14
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline.
is resource is a practice tool based on ASCO
®
practice guidelines and is not intended to substitute for
the independent professional judgment of the treating physician. Practice guidelines do not account for
individual variation among patients. is pocket guide does not purport to suggest any particular course of
medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines
and additional information are available at www.asco.org/breast-cancer-guidelines. Copyright ©2020 by
American Society of Clinical Oncolog y. All rights reserved.
Source
Allison K, et al: Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline
update. J Clin Oncol doi: 10.1200/JCO.19.02309
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
ASCOEST20123a
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines.
Abbreviations
ASCO, American Society of Clinical Oncology; DCIS, Ductal carcinoma in situ; CAP,
College of American Pathologists; ER, estrogen receptor; NBF, neutral buffered formalin; IHC
immunohistochemistry; PgR, progesterone receptor; SOP, standard operating procedure
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient